EVs have also been used to deliver CRISPR/Cas9 vector (Figure 7), coding for Cas9 plasmid and sgRNA specific for the KRAS G12D mutation, to disrupt KRAS activity at the gene level in in vitro and in vivo pancreatic cancer models [115]. Here, KRAS is linked to familial pancreatic carcinoma.